Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Koninklijke Philips NV | 55 |
| 2 | Janssen Pharmaceutica NV | 48 |
| 3 | Egalet Ltd | 35 |
| 4 | Noven Pharmaceuticals Inc | 35 |
| 5 | Amicus Therapeutics Inc | 31 |
| 6 | Aquestive Therapeutics Inc | 24 |
| 7 | The University of Texas System | 20 |
| 8 | Chienna BV | 19 |
| 9 | Entero Therapeutics Inc | 19 |
| 10 | GridAI Technologies Corp | 19 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 691 |
| 2 | A61P | Therapeutic activity (drug indications) | 493 |
| 3 | C07D | Heterocyclic compounds | 135 |
| 4 | A61L | Sterilising / disinfecting materials | 63 |
| 5 | G01N | Investigating / analysing materials | 60 |
| 6 | C08L | Polymer compositions (blends) | 59 |
| 7 | Y02A | Climate change adaptation | 48 |
| 8 | Y10T | Cross-reference (technical subjects) | 46 |
| 9 | A61M | Devices for introducing media into the body | 41 |
| 10 | C12N | Microorganisms, enzymes | 38 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Receptor Mechanisms and Signaling | 3 |
| 2 | Chemical Reactions and Mechanisms | 1 |
| 3 | Cholinesterase and Neurodegenerative Diseases | 1 |
| 4 | Neurobiology and Insect Physiology Research | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Dick de Zeeuw | University of Groningen | 9 |
| 2 | Pierre M. Laduron | Janssen (Belgium) | 9 |
| 3 | Henry N. Wagner | Johns Hopkins University | 7 |
| 4 | Alan A. Wilson | Johns Hopkins University | 7 |
| 5 | Michael Kassiou | Australian Nuclear Science and Technology Organisation | 7 |
| 6 | Robert F. Dannals | Johns Hopkins University | 7 |
| 7 | Harbans Lal | University of Rhode Island | 6 |
| 8 | A. Wauquier | Janssen (Belgium) | 5 |
| 9 | Andrew Katsifis | Australian Nuclear Science and Technology Organisation | 5 |
| 10 | C. J. E. Niemegeers | Janssen (Belgium) | 5 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Muscarinic M2 receptors in bovine tracheal smooth muscle: discrepancies between binding and function | 1988 | 156 | Ion channel regulation and function |
| Axoplasmic transport of muscarinic receptors | 1980 | 95 | Lipid Membrane Structure and Behavior |
| STEREOSPECIFIC <i>IN VlTRO</i> BINDING OF [<sup>3</sup>H]DEXETIMIDE TO BRAIN MUSCARINIC RECEPTORS | 1979 | 74 | Neuroscience and Neuropharmacology Research |
| Purification of muscarinic acetylcholine receptors by affinity chromatography. | 1983 | 68 | Receptor Mechanisms and Signaling |
| Synthesis of radiotracers for studying muscarinic cholinergic receptors in the living human brain using positron emission tomography: [11C]dexetimide and [11C]levetimide | 1988 | 60 | Neuroscience and Neuropharmacology Research |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Dexetimide?
Which organizations have the most patents related to Dexetimide?
What are the primary research topics associated with Dexetimide in the scientific literature?
What key research has been published on Dexetimide's interaction with muscarinic receptors?
How has patent activity for Dexetimide changed in recent years?